Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Charles River Laboratories Intl (NY: CRL )

194.19 +6.29 (+3.35%)
Official Closing Price Updated: 7:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Charles River Laboratories Intl

< Previous 1 2 3 4 5 Next >
Charles River Q3 Earnings: CEO Notes Improved Biotech Funding And Stabilizing Demand - Here's Why
Charles River Labs Q3 revenue of $1.01 billion surpassed expectations; however, revenue declined 1.6% YoY, and operating margin dropped to 11.6% amid restructuring costs. 
Via Benzinga
S&P 500, Dow Hit Record Highs After Trump Win; Fear Index Drops 20%
Market surges to record highs after Trump's election, Republicans win Senate majority. Tech and small-caps up, VIX drops 22%. 
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
P/E Ratio Insights for Charles River
Via Benzinga
This Ferguson Enterprises Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Evaluating Charles River: Insights From 12 Financial Analysts
Via Benzinga
The Analyst Verdict: Charles River In The Eyes Of 10 Experts
Via Benzinga
This Alibaba Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
This Netflix Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
Via Benzinga
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences. 
Via Benzinga
Magnificent 7 Miss Out, 2 Cybersecurity Stocks Stand Firm, Retailers Lag In Volatile August: Here Are The Top S&P 500 Gainers And Losers
The equity market was volatile in August, with the weakness seen early in the month dissipating amid a rise in rate-cut bets. 
Via Benzinga
Topics Stocks
Exposures US Equities
Critical Insights From Charles River Analyst Ratings: What You Need To Know
Via Benzinga
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers. 
Via Benzinga
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway
Oragenics announced its lead candidate, ONP-002, for treating concussion, which shows no cardiotoxicity in studies. Designed for nasal delivery to the brain, ONP-002 aims to address the significant... 
Via Benzinga
Boot Barn To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Wall Street Ends Wednesday In The Red As Risk Sentiment Remains Fragile: S&P 500 Movers At The Close
U.S. markets close lower on Wednesday after bounce back on Tuesday, with small caps hit hardest. Investors assess economic outlook and Fed rate cut. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Demystifying Charles River: Insights From 4 Analyst Reviews
Via Benzinga
The Analyst Verdict: Charles River In The Eyes Of 4 Experts
Via Benzinga
Charles River Laboratories Stock Sinks As It Warns Of Continued Biotech Demand Slump, Lowers Forecast
Charles River Laboratories reported Q2 2024 revenue of $1.03 billion, a 3.2% decrease year-over-year, surpassing the $1.024 billion consensus. Adjusted EPS rose to $2.80 from $2.69. The company revised... 
Via Benzinga
Charles River Labs Plummets 17% On 'Bleaker' Expectations For 2024
Pharmaceutical demand hit the skids in the second quarter and isn't expected to improve this year. 
Via Investor's Business Daily
Apple To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
These Nike Analysts Are No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
The Analyst Landscape: 7 Takes On Charles River
Via Benzinga
Evaluating Charles River: Insights From 7 Financial Analysts
Via Benzinga
CRL Stock Earnings: Charles River Beats EPS, Beats Revenue for Q1 2024
CRL stock results show that Charles River beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
The 7 Best Growth Stocks to Buy in May 2024
Find real bargains in this marketplace with these seven best growth stocks to buy today for your portfolio. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Top 3 Healthcare Stocks to Buy in March 2024
There are still bargains to be had in the medical space. These are three top healthcare stocks to buy today. 
Via InvestorPlace
Betting on Bitcoin: Does Coinbase Stock’s Surge Signal a Buy?
vBitcoin has exploded higher over the past month setting an all-time record. That’s excellent news for Coinbase Global and COIN stock. 
Via InvestorPlace
Thermo Fisher Stock Lights Up The Board, Soars 40% In 5 Months
Thermo Fisher stock has risen more than 40% since October. Additionally, it's closed higher nine of the past 11 trading sessions. 
Via Investor's Business Daily
The Next Johnson & Johnson? 3 Healthcare Stocks That Investors Shouldn’t Ignore.
Looking for the next generational winner in healthcare stocks? These are three of the top prospects today. 
Via InvestorPlace
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.